Laureaten Wetenschappelijke Grants 2020
Om de twee jaar lanceert Stichting tegen Kanker een oproep naar onderzoeksprojecten in de oncologie om fundamenteel, translationeel en klinisch onderzoek te financieren. Dit jaar zijn 63 innoverende en veelbelovende kankeronderzoeksprojecten van verschillende universiteiten en ziekenhuisinstellingen in het hele land geselecteerd. Dankzij de vrijgevigheid van de donateurs kan € 23,8 miljoen over de projecten worden verdeeld.
De financiering is als volgt verdeeld:
- In fundamenteel onderzoek: 30 projecten geselecteerd voor een totaal budget van € 13 284 989.
- In translationeel en klinisch onderzoek: 27 projecten geselecteerd voor een totaal budget van € 8 745 680.
- De gerichte oproep voor kankers gelinkt aan de blootstelling aan “Asbest” heeft toegelaten om 6 projecten te selecteren voor een totaal budget van € 1 771 000.
Fundamenteel onderzoek: 30 projecten - € 13 284 989
Onderzoeksteam(s)
Organisatie(s)
Bedrag
Type van kanker
Type van behandeling
Titel van het project
Aerts Stein
KU Leuven
578 000 €
OncoAI - a machine-learning framework to predict cancer cell vulnerability at the gene-regulatory level
Berx Geert
UGent
450 000 €
Borstkanker
Defining the role of ZEB1 in tumour initiation and progression of basal-like breast cancer
Blanpain Cédric
ULB
720 000 €
Defining the mechanisms of clonal competition upon oncogenic transformation
Bollen Mathieu
KU Leuven
435 000 €
Phospho-regulation at the crossroads of cell proliferation and DNA-damage control
Carmeliet Geert
KU Leuven
462 000 €
Borstkanker
Metabolic vulnerability of breast tumor cells during bone metastasis formation
Chariot Alain
ULiège
578 000 €
Dikkedarmkanker en borstkanker
Oncogenic tRNA modifications and their targets
De Keermaecker Kim
KU Leuven
400 000 €
Leukemie
Doelgerichte therapie, chemotherapie
Serine/glycine synthesis addiction in acute lymphoblastic leukemia and resulting therapeutic opportunities
De Preter Katleen
UGent
356 000 €
Neuroblastoom
Characterizing regulatory heterogeneity in high-risk neuroblastoma
Detours Vincent
ULB
337 424 €
Schildklierkanker en pancreaskanker
Reappraisal of cancer morphology and its cellular and transcriptional determinants with unsupervised artificial intelligence, single nuclei and spatial transcriptomics
De Wever Olivier
UGent
400 000 €
Immunotherapie en radiotherapie
Impact of cancer-associated fibroblasts and their secretome on innate-adaptive immune cross-talk upon irradiation
Feron Olivier
UCLouvain
488 000 €
To reconcile the location of tumor microenvironment-driven mesenchymal-like cancer cells and their contribution to cancer progression.
Fuks François
ULB
569 000 €
Borstkanker
Unravelling the role of epitranscriptomics in aggressive breast cancer by means of innovative technologies
Halder Georg
KU Leuven
570 800 €
Leverkanker
Suppressing the evolution of liver cancer into highly aggressive forms
Jacquemin Patrick
UCLouvain
240 000 €
Pancreaskanker
Identification of pancreatic cell types in the origin of human pancreatic cancer
Laoui Damya & Aboubakar Frank
VUB & UCLouvain
436 976 €
Longkanker
Immunotherapie
cDC2s: new players in the tumor microenvironment and cancer immunotherapy
Lucas Sophie
UCLouvain
578 000 €
Immunotherapie
Deciphering molecular and cellular mechanisms of action of anti-GARP:TGF-β1 therapy
Mazzone Massimiliano
KU Leuven
542 000 €
Immunotherapie
Arachidonic acid metabolism, a cross point between "bad" and "good" macrophages in cancer: a novel therapeutic perspective?
Rapino Francesca
ULiège
337 500 €
“tRNA actors” heterogeneity: a new identifier of cancer stem cells
Swinnen Johan
KU Leuven
382 400 €
Prostaatkanker
Exploiting acquired vulnerabilities in fatty acid metabolism to overcome therapy resistance in castration resistant prostate cancer
Tejpar Sabine
KU Leuven
337 500 €
Dikkedarmkanker
Immunotherapie
Coevolution of epithelium and immune response in colorectal cancer: comprehensive longitudinal analysis and manipulation of crosstalk leading to exhausted responses in dedicated mouse models.
Thienpont Bernard
KU Leuven
506 000 €
Longkanker
Inhibiting resistance acquisition by epigenetically altering tumour heterogeneity
Vandenabeele Peter
UGent
360 000 €
Dikkedarmkanker
Immunotherapie
Improving cancer therapy by modulating cell death and the microbiome in the gut
Van den Broeke Anne & Georges Michel
Institut Bordet & ULiège
448 000 €
Leukemie
Tracking tumor evolution and drivers of oncogenic switch: lessons from single cells, viruses and sheep
Van Ginderachter Jo
VUB
445 991 €
Immunotherapie
Selective elimination of tumor-infiltrating regulatory T cells via IL-1R2 targeting
Van Gastel Nick
Institut de Duve
480 000 €
Leukemie
Understanding metabolic crosstalk in the leukemic bone marrow niche
Translationeel en klinisch onderzoek: 27 projecten - € 8 745 680
Onderzoeksteam(s)
Organisatie(s)
Bedrag
Type van kanker
Type van behandeling
Titel van het project
Albersen Maarten
KU Leuven
395 000 €
Peniskanker
Doelgerichte therapie
Developing personalized treatment for advanced penile cancer trough establishment of Patient-Derived Tumor Xenografts (PDTXs).
Berx Geert
UGent
399 920 €
Dikkedarmkanker
Doelgerichte therapie
Preclinical validation of novel plastistatic therapy for malignant colon cancer
Borbath Ivan, Peeters Marc, Van Laethem Jean-Luc & Van Cutsem Eric
UC Louvain, UAntwerpen, ULB - Erasme & KU Leuven
398 000 €
Galblaaskanker
Doelgerichte therapie
SAFIR-ABC10: molecular screening for precision medicine in advanced biliary cancers
Bormans Guy
KU Leuven
325 000 €
Radiotherapie
Peptide based CXCR4 targetting for PET imaging and radionuclide therapy
Caers Jo
ULiège
380 000 €
Multipel myeloom
Immunotherapie
Novel antigen identification for multiple myeloma
Cools Jan
KU Leuven
400 000 €
Leukemie
Doelgerichte therapie
PSEN1-selective gamma-secretase inhibition for the treatment of T-cell acute lymphoblastic leukemia
Creytens David & Hernot Sophie
UGent & VUB
86 500 €
Chirurgie
Peroperative ex vivo cancer margin detection using fluorescence labelled single-domain antibodies
De Neve Wilfried, Van Gestel Dirk & Remouchamps Vincent
UGent & ULB & CHU Namur - UCLouvain
400 000 €
Borstkanker
Radiotherapie
Maximizing the ratio of radiotherapy survival benefit over radiation-related morbidity and mortality in patients requiring breast and regional lymph nodes treatment. A multicenter study using the prone crawl radiotherapy technique
Desmedt Christine, Vermeulen Peter, Donckier de Donceel Vincent
KU Leuven & U Antwerpen & ULB, Bordet
399 125 €
Borstkanker en leveruitzaaiingen
Clinical, experimental and molecular characterization of liver metastases from breast cancer patients.
Flamen Patrick
ULB, Bordet
299 920 €
Longkanker
Radiotherapie & immunotherapie
Molecular imaging of cancer-associated fibroblasts in NSCLC treated with immune-checkpoint inhibitors.
Gallez Bernard
UCLouvain
250 000 €
Huidkanker
Characterization of skin melanomas by Electron Paramagnetic Resonance
Humblet-Baron Stéphanie
KU Leuven
390 000
Leukemie en lymphoom
Immunotherapie
In-depth investigation of patient immune signature after CD19 CAR T-cell therapy
Kridelka Frédéric
ULiège
200 000 €
Baarmoederhalskanker
Lymph node profiling in advanced cervical cancer
Lambrechts Diether
KU Leuven
379 960 €
Immunotherapie
Alternative RNA splicing as a predictor of response to checkpoint immunotherapy
Nuyts Sandra
KU Leuven
400 000 €
Hoofd- en halskanker
Immunotherapie
Prediction of RT response in head and neck cancers by assessment of the clonal repopulation dynamics
Piccart Martine
ULB, Bordet
400 000 €
Borstkanker
AURORA - Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer
Sotiriou Christos
Institut Jules Bordet
238 000 €
Borstkanker
Mapping tumor and immune cell architecture in TNBC using spatial transcriptomics and single nuclei sequencing
Speleman Franki
UGent
200 000 €
Neuroblastoom
Doelgerichte therapie
Scrutinizing selective Aurora kinase A inhibition as a novel therapeutic strategy for neuroblastoma
Sprangers Ben
KU Leuven
345 000 €
Immunotherapie
Developing approaches to allow the safe and effective use of checkpoint inhibitors in solid organ transplant patients
Taghon Tom
UGent
380 000 €
Thymuskanker
Functional characterization and expansion of thymus seeding precursors in human.
Topal Baki
UZ Leuven
200 000 €
Pancreaskanker
Immunotherapie
Effects of immunotherapy on the cellular landscape and immune milieu in locally advanced pancreatic ductal adenocarcinoma
Van den Eynde Marc, Carrasco Javier, Liberale Gabriele & Raes Jeroen
UCLouvain, GHdC, Institut Jules Bordet & KU Leuven
399 252 €
Darmkanker
Immonutherapie
The microbiome in colorectal metastases: nature and impact on local immune and inflammatory response, disease evolution and response to therapy
Vandekerckhove Bart
UGent
365 145 €
Longkanker
Immunotherapie
Improving Neo-epitope Identification in lung cancer patients using Mass spectrometry and Next generation sequencing (INI-M&N)
Van Craenenbroeck Emeline
UAntwerpen
382 900 €
Borstkanker
Discovering the role of titin (TTN) in anthracycline-induced cardiac dysfunction in breast cancer
Vanhaudenhuyse Audrey
ULiège
399 935 €
Hypnose
Hypnosis and cognitive trance on cancer patients: impact on quality of life and neurophysiology
Wildiers Hans
KU Leuven
100 000 €
Borstkanker
Mechanisms involved in metastasis of luminal breast cancer
Asbest: 6 projecten - € 1 771 000
Onderzoeksteam(s)
Organisatie(s)
Bedrag
Thema
Titel van het project
Feron Olivier
UCLouvain
400 000 €
Mesothelioom & immunotherapie
In situ induction of immunogenic cell death to boost DC-based immunotherapy of peritoneal mesothelioma
Halder Georg
KU Leuven
400 000 €
Mesothelioom & doelgerichte therapie
Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesothelioma
Janssens Veerle
KU Leuven
325 000 €
Mesothelioom
Protein Phosphatase 2A dysfunctions in malignant pleural mesothelioma: oncogenic mechanisms and therapeutic opportunities
Lion Eva, Germonpré Paul & Valcke Yvan
U Antwerpen & AZ Middelares & AZ Niklaas
200 000 €
Mesothelioom & immunotherapie
Boosting the response rate to standard treatment with upfront dendritic cell vaccination in patients with malignant pleural mesothelioma
Van Camp Guido
UAntwerpen
223 000 €
Mesothelioom
Towards a novel generation detection biomarkers for malignant pleural mesothelioma in clinical practice
